SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility following a blockbuster earnings report that showcased record-breaking revenue and profit margins driven by insatiable AI-related memory demand. While bulls are touting a transformative super-cycle and attractive forward valuations, the stock is currently facing short-term selling pressure as market participants weigh profit-taking after a rapid run-up against broader macroeconomic concerns.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as investors react to a short report from Muddy Waters, which the company and its CEO, Anthony Noto, have actively countered through a firm rebuttal, legal threats, and Noto's own significant open-market share purchase. The community is sharply divided, with many retail investors viewing the short seller's move as a manipulative attempt to profit from exit liquidity, while others are closely debating the accounting allegations and the stock's potential for a short-term recovery.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is seeing heightened volatility as investors grapple with conflicting signals from a rising dollar and ongoing geopolitical instability in the Middle East, leading to intense debate over whether current price action represents a temporary dip or a breakdown of the metal's safe-haven status. The community is actively discussing the impact of institutional short-selling and algorithmic trading, with many focused on whether recent price pressure is a structural shift or a prime accumulation opportunity for those betting on long-term industrial demand and supply deficits.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is currently trending as investors focus on the company's strong revenue growth and record financial performance leading up to its quarterly earnings report. The community is actively debating the stock's valuation, with many bullish participants comparing its potential to industry peers like Robinhood while others express frustration over historical price volatility and market manipulation concerns.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme market volatility following its recent IPO, with community debate centered on whether its battle-tested drone software and defense-sector ties justify its rapid valuation surge. Traders are closely monitoring the stock as a potential high-momentum runner, though many are cautious about its long-term stability given the lack of substantial trailing revenue.

United States Commodity Funds LLC - United States Brent Crude Oil Fund

The United States Brent Oil Fund is trending as investors monitor escalating geopolitical tensions in the Middle East and their impact on global supply chains. Market participants are actively discussing the implications of disrupted tanker traffic, potential energy infrastructure risks, and shifting production quotas that have heightened volatility for commodity-focused portfolios.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing intense volatility and record-high trading volume as traders debate whether its parabolic rally is a sustainable super-cycle in memory demand or an unsustainable bubble nearing a major correction. Market participants are intensely focused on the upcoming Micron earnings, using Sandisk as a high-beta sympathy play that bulls believe will continue to surge while bears prepare for a potential rug pull.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing heightened volatility as investors weigh the stock's traditional safe-haven status against a backdrop of geopolitical tension, rising oil prices, and shifting expectations for Federal Reserve rate policy. Community sentiment remains deeply polarized, with many market participants actively debating whether the metal is currently oversold or facing a broader structural breakdown amid strong dollar strength and institutional repositioning.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh recent reports of minor production-related wiring issues against growing optimism regarding massive potential aircraft orders from China and a robust defense contract pipeline. While the stock continues to face short-term volatility from broader market concerns and delivery pacing, the community remains intensely divided between those betting on an institutional-led recovery fueled by long-term backlogs and those frustrated by persistent quality control headlines and management's extended profitability timelines.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is experiencing intense market volatility as investors weigh a double earnings beat against weak full-year guidance and persistent concerns over traffic, portion sizes, and leadership. Community sentiment is deeply divided, with many traders capitalizing on aggressive short positions and technical volatility, while some long-term holders continue to debate the company's competitive positioning against rivals like CAVA.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter.</li><li>The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others.</li><li>The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;</li></ul>&nbsp;Shares of Quoin Pharmaceuticals (QNRX) jumped as much as 39% on Tuesday after the company announced that the target loading concentrations for its two topical Rapamycin delivery technologies have been successfully achieved.A Rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/11/3185408/0/en/Quoin-Pharmaceuticals-Announces-Achievement-of-Topical-Rapamycin-Target-Loadings-for-Two-Proprietary-Delivery-Technologies.html">said</a>.<h2 class="st-heading-2">Path Forward</h2>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter. The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others. Microcystic lymphatic malformations are benign vascular anomalies characterized by a collection of small, abnormal lymphatic vessels and cysts, often appearing as small, skin-colored to pinkish or even dark, blister-like vesicles on the skin.Venous malformations, meanwhile, are present at birth, but not always visible, and are the most common type of vascular malformation. They are caused by veins that have not developed normally, resulting in tangled, enlarged vessels. Symptoms can include bluish or purplish spots, swelling, and pain.Neither microcystic lymphatic malformations nor venous malformations have FDA-approved treatments.<h2 class="st-heading-2">Executive Take Away</h2>According to Quoin CEO Michael Myers, initiating clinical development in microcystic lymphatic malformations and venous malformations will be complementary to the company’s pipeline.The firm is now looking forward to the commencement of pivotal studies for QRX003 in Netherton Syndrome by the end of the year, with the help of the financing of up to $105.3 million closed in October. Quoin’s overall pipeline comprises four products in development for Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Scleroderma, among others.<blockquote>“We believe that rapamycin loading concentrations of 4% and 5% in these proprietary delivery systems could potentially provide competitive advantages over other topical rapamycin formulations currently in development with similar drug loadings due to the ability of our technologies to optimize delivery of the drug at the target sites.” &nbsp; - Michael Myers, CEO, Quoin.</blockquote><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QNRX">QNRX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.QNRX stock is down by 59% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/chamath-palihapitiya-talks-about-us-achilles-heel-when-it-comes-to-rare-earths/cLPdHr9REPH">Chamath Palihapitiya Talks About US' Achilles Heel When It Comes To Rare Earths</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

Equity

Quoin Pharmaceuticals (QNRX) became the top-four trending ticker on Stocktwits on Friday morning after the stock jumped nearly 300% after the company announced that it has entered into a securities purchase agreement with new healthcare-focused institutional investors, with the potential to raise $104.5 million in gross proceeds.The late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases said that this purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.The firm added that&nbsp;the private placement was priced at a premium to the company’s prior day’s closing stock price. Quoin said that the financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others.Retail sentiment on <a href="https://stocktwits.com/symbol/QNRX">Quoin</a> jumped to ‘extremely bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Quoin said it will issue an aggregate of 1,993,940 American Depository Shares (ADSs) and accompanying warrants to purchase up to an aggregate of 7,975,760 ADSs, at a combined purchase price of $8.25 per ADS and accompanying warrants.The company said it intends to use the upfront net proceeds for general corporate purposes, which may include operating expenses, research and development, including completion of clinical development of QRX003 for Netherton Syndrome, working capital, future acquisitions, and general capital expenditures.&nbsp;The aggregate net proceeds are expected to be sufficient to fund the company into 2027. Shares of Quoin have gained nearly 41% this year and have jumped 76% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kalshi-doubles-valuation-to-5-b-in-latest-funding-round-report/ch6aClnR3SM">Kalshi Doubles Valuation To $5B In Latest Funding Round: Report</a>

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Shares of Quoin Pharmaceuticals saw increased retail chatter on Wednesday after the company announced positive initial clinical data from its ongoing investigational new drug Pediatric Peeling Skin Syndrome (PSS) study evaluating QRX003.Twelve weeks of treatment produced a clear improvement in the patient's skin condition compared to initial baseline measurements.&nbsp;The stock closed at $7.65 on Wednesday, rising 20.3% during the day, but slipped 8% to $7.04 in after-hours trading.Clinical endpoints such as The Investigator's Global Assessment (IGA), Modified Ichthyosis Area Severity Index (M-IASI), and Children's Dermatology Life Quality Index (CDLQI) showed positive changes.&nbsp;The patient's IGA score changed from severe to mild, M-IASI decreased from 36 to 12, and CDLQI, the quality of life measure, fell from 19 to 11. The study reported no adverse events while administering QRX003 to patients.Quoin will extend the patient's treatment while performing additional clinical evaluations after 24 weeks of therapy.&nbsp;The firm continues to progress QRX003 through late-stage clinical trials targeting Netherton Syndrome, another uncommon skin condition.Peeling Skin Syndrome is a rare genetic disorder that manifests through excessive outer skin shedding, leading to persistent pain and itching.&nbsp;Without any existing approved treatments, the promising results from QRX003 trials suggest its potential importance if future studies confirm the positive outcomes.CEO Michael Myers stressed the clinical importance of observed improvements and pointed out QRX003's potential to become the first approved therapy for PSS, noting plans to expand the study internationally.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,314% surge in 24-hour message volume.One user noted that some investors with less conviction tend to sell just before market close, expressing hope that the stock would open at $20.&nbsp;<stembedurl>https://stocktwits.com/89gt/message/614698425</stembedurl>Another user highlighted the stock’s potential for rapid movement due to its very low float and recent positive news.<stembedurl>https://stocktwits.com/MasterofThePennies/message/614637863</stembedurl>The stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data

The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Current Price	$7.84
Prev Close	$8.14
Open	$7.91
Dividend Yield	0.00%
50-Day Moving Average	$9.24
Beta	0.45
Avg. Volume	30,167.55
PE Ratio	-0.02

52-Week High	$41.80
52-Week Low	$5.01
Market Capitalization	$4.79M
EPS (Annual)	-$67.22
Price to Book	-3.94
Revenue Per Employee	$0.00

QNRX
Quoin Pharmaceuticals Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest QNRX News

QNRXQuoin Pharmaceuticals Ltd - ADR